Precision medicine in non-small cell lung cancer: Current applications and future directions Review
| Authors: | Yang, S. R.; Schultheis, A. M.; Yu, H.; Mandelker, D.; Ladanyi, M.; Büttner, R. |
| Review Title: | Precision medicine in non-small cell lung cancer: Current applications and future directions |
| Abstract: | Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there are highly effective targeted therapies against EGFR, ALK, ROS1, BRAF, TRK, RET, and MET. In addition, investigational therapies for KRAS, NRG1, and HER2 have shown promising results and may become standard-of-care in the near future. In parallel, immune-checkpoint therapy has emerged as an indispensable treatment modality, especially for patients lacking actionable oncogenic drivers. While PD-L1 expression has shown modest predictive utility, biomarkers for immune-checkpoint inhibition in NSCLC have remained elusive and represent an area of active investigation. Given the growing importance of biomarkers, optimal utilization of small tissue biopsies and alternative genotyping methods using circulating cell-free DNA have become increasingly integrated into clinical practice. In this review, we will summarize the current landscape and emerging trends in precision medicine for patients with advanced NSCLC with a special focus on predictive biomarker testing. © 2020 Elsevier Ltd |
| Keywords: | immunohistochemistry; oncoprotein; overall survival; single nucleotide polymorphism; genetics; mutation; proto-oncogene proteins; review; advanced cancer; drug efficacy; drug approval; cancer patient; outcome assessment; polymerase chain reaction; cancer immunotherapy; progression free survival; carcinoma, non-small-cell lung; lung neoplasms; cancer screening; protein tyrosine kinase; mutational analysis; tumor marker; cancer resistance; protein tyrosine kinase inhibitor; lung tumor; fluorescence in situ hybridization; protein-tyrosine kinases; trend study; lung biopsy; tissue fixation; cytodiagnosis; turnaround time; personalized medicine; non small cell lung cancer; molecularly targeted therapy; genotyping; fine needle aspiration biopsy; sanger sequencing; humans; human; precision medicine; pembrolizumab; osimertinib; liquid biopsy; biomarkers, tumor; tumor mutational burden; histological and molecular diagnostics; lung cancer diagnostics; resistance to egfr-tkis |
| Journal Title: | Seminars in Cancer Biology |
| Volume: | 84 |
| ISSN: | 1044-579X |
| Publisher: | Academic Press Inc., Elsevier Science |
| Date Published: | 2022-09-01 |
| Start Page: | 184 |
| End Page: | 198 |
| Language: | English |
| DOI: | 10.1016/j.semcancer.2020.07.009 |
| PUBMED: | 32730814 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 August 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work